Artificial intelligence can predict risk of recurrence for women with common breast cancer
October 15th 2021They added that this is one of the first proofs of concept illustrating the power of an AI model for identifying parameters associated with relapse that the human brain could not detect.
Read More
FDA grants trastuzumab deruxtecan breakthrough therapy designation for breast cancer
October 5th 2021The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.
Read More